U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07860554) titled 'Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer' on Sept. 25.
Brief Summary: This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope....